CJC-1295 (without DAC) vs Vesilute
Well Studied vs Moderate Research
synergistic Mechanism-based · 47% CJC-1295 (without DAC) and Vesilute work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
CJC-1295 (without DAC) Vesilute
Weight 3,367.97 Da 262 Da
Half-life 30 minutes - 2 hours Not established
Chain 30 amino acids 2 amino acids
Type GHRH analog Dipeptide bioregulator
Key Benefits
CJC-1295 (without DAC)
01 Preserves natural GH pulsatility
02 Minimal side effects
03 No receptor desensitization
04 Precise GH release control
05 4x greater receptor affinity than native GHRH
Vesilute
01 Supports bladder and urinary tract function
02 May improve prostate health in men
03 Regulates smooth muscle function
04 Enhances pelvic tissue blood flow
05 Supports cellular regeneration
06 Part of comprehensive Khavinson bioregulator protocols
07 Well-tolerated in research
08 Oral bioavailability as small dipeptide
Dosing Protocols
CJC-1295 (without DAC)
100-300mcg per injection / 2-3 times daily (morning, post-workout optional, bedtime)
Anti-Aging/Wellness 100mcg 2x daily (morning and bedtime)
Body Composition 100-150mcg 3x daily (morning, post-workout, bedtime)
Maximum GH Release 200mcg 2-3x daily with GHRP
Sleep Enhancement 100-200mcg Once at bedtime
Vesilute
10-20 mg per day / Daily for 10-20 consecutive days (Khavinson bioregulator cycle)
Standard protocol 10-20 mg Daily for 10-20 days
Maintenance 20 mg 2-3 cycles yearly
Side Effects
CJC-1295 (without DAC)
Generally well-tolerated at recommended doses
Temporary facial flushing/warmth (5-10 minutes post-injection)
Vesilute
Generally well-tolerated
Injection site reactions (mild, if injectable)
Minimal reported side effects
Contraindications
Active cancer (due to growth-promoting effects)
Diabetic retinopathy
Severe kidney disease
Pregnancy or breastfeeding
Known hypersensitivity to peptide components
Active urinary tract infection (treat first)
Pregnancy or breastfeeding
Prostate cancer (consult physician)
Research Evidence
CJC-1295 (without DAC) Vesilute
Status Well Studied Moderate Research
References 5 studies 3 studies
Latest November 2024 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.